ICON experts frequently author or contribute to industry trade press. The following are some recent articles.
Clinical Data Management
In this article, Michael Phillips, discusses the ways in which machine learning can replace or augment traditional data review approaches.
The human condition
In this article, Patricia Murphy discusses how the industry needs to make rare disease clinical trials more human.
Making accessibility strategy part of your rare disease trial planning
In this article, Laura Iliescu, discusses strategies to improve inclusion of people with disabilities in rare disease trials.
How decentralised and hybrid clinical trials can support subject recruitment and retention to support clinical trial success
Read Laney Preheim's article in International Pharmaceutical Industry.
Diverse teams drive great performance
Steve Cutler participated in the Business & Finance CEO Q&A in which he outlined his ambitions and priorities for ICON.
Transforming clinical trials in a rapidly shifting landscape
Dr Ute Berger outlines how ICON is transforming clinical trials in a rapidly shifting landscape in the Executive Interview in Drug Development & Delivery.
Data doesn't cut it - Payer engagement requires a humanistic approach
Earlene Biggs shares the key elements of an effective strategy to engage with healthcare decision-makers.
Developing mRNA vaccine technology
In this article, Dinah Knotts speaks about mRNA vaccine technology and what further opportunities it can offer in fighting infectious diseases.
Decentralised clinical trials and sites: friend or foe?
Emily Mitchell contributes to this piece in Clinical Trials Arena on the role of sites in a DCT setting.
Due diligence and beyond
Dr. Sandra Eagle outlines how due diligence has evolved from a discrete standalone technical assessment of an asset, to now being an integrated part of the holistic development continuum of an asset.